Literature DB >> 28508878

Incontinence: The dilemma with comparing efficacy of OAB treatments.

Arun Sahai1, Sachin Malde1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28508878     DOI： 10.1038/nrurol.2017.67

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.

Authors:  Adrian Wagg; Gerhard Compion; Amanda Fahey; Emad Siddiqui
Journal:  BJU Int       Date:  2012-03-12       Impact factor: 5.588

2.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.

Authors:  H C Bucher; G H Guyatt; L E Griffith; S D Walter
Journal:  J Clin Epidemiol       Date:  1997-06       Impact factor: 6.437

3.  Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.

Authors:  Christopher R Chapple; Jameel Nazir; Zalmai Hakimi; Sally Bowditch; Francis Fatoye; Florent Guelfucci; Amine Khemiri; Emad Siddiqui; Adrian Wagg
Journal:  Eur Urol       Date:  2017-02-11       Impact factor: 20.096

4.  Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).

Authors:  Marcus J Drake; Christopher Chapple; Ahmet A Esen; Stavros Athanasiou; Javier Cambronero; David Mitcheson; Sender Herschorn; Tahir Saleem; Moses Huang; Emad Siddiqui; Matthias Stölzel; Claire Herholdt; Scott MacDiarmid
Journal:  Eur Urol       Date:  2016-03-08       Impact factor: 20.096

5.  The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.

Authors:  Sender Herschorn; Alfred Kohan; Philip Aliotta; Kurt McCammon; Rajagopalan Sriram; Steven Abrams; Wayne Lam; Karel Everaert
Journal:  J Urol       Date:  2017-02-01       Impact factor: 7.450

6.  Indirect treatment comparison (ITC) of medical therapies for an overactive bladder.

Authors:  Aneta Obloza; Joshua Kirby; Derrick Yates; Philip Toozs-Hobson
Journal:  Neurourol Urodyn       Date:  2017-02-21       Impact factor: 2.696

7.  Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Authors:  Anthony G Visco; Linda Brubaker; Holly E Richter; Ingrid Nygaard; Marie Fidela R Paraiso; Shawn A Menefee; Joseph Schaffer; Jerry Lowder; Salil Khandwala; Larry Sirls; Cathie Spino; Tracy L Nolen; Dennis Wallace; Susan F Meikle
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

8.  Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.

Authors:  Michael B Chancellor; Alon Yehoshua; Catherine Waweru; Denise Globe; I-Ning Cheng; Karen L Campbell; Manher Joshi; Riya Pulicharam
Journal:  Int Urol Nephrol       Date:  2016-04-01       Impact factor: 2.370

Review 9.  Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).

Authors:  Marta Rossanese; Giacomo Novara; Ben Challacombe; Alessandro Iannetti; Prokar Dasgupta; Vincenzo Ficarra
Journal:  BJU Int       Date:  2014-07-27       Impact factor: 5.588
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.